LIN-2102

N/A

Report date: 2024/03/15 15:31:06

Base Information

Drug NameLIN-2102
Drug Alias NameLIN-2102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionComplement system proteins inhibitors
TargetsComplement system proteins
Therapy Area/IndicationsAcute Kidney InjuryGlomerulonephritis, IGAMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesLinnuo (Shanghai) Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLinnuo (Shanghai) Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsAcute Kidney InjuryGlomerulonephritis, IGAMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A